Category: Zacks Small Cap Research
By Brian Marckx, CFANASDAQ:BMRAREAD THE FULL BMRA RESEARCH REPORTBiomerica’s IgG Antibody Test Used to Significantly Reduce Ulcerative Colitis Symptoms, Improve QoLResults of an n=97 randomized, investigator-blinded food-exclusion study showed that B ...
By Brian Marckx, CFANASDAQ:NAOVREAD THE FULL NAOV RESEARCH REPORTZacks SCR Senior Med-Tech analyst and Director of Research Brian Marckx, CFA has initiated coverage of NanoVibronix, Inc. with a $9.00/share price target. See below for free access to h ...
By Anita Dushyanth, PhDNYSE:NNVCREAD THE FULL NNVC RESEARCH REPORTINITIATING COVERAGENanoViricides, Inc. (NYSE:NNVC) is an early stage nano-pharmaceutical company that was first listed in 2005 and became a reporting company the following year. The co ...
By David Bautz, PhDTSX:ATE.VREAD THE FULL ATE.V RESEARCH REPORTFinancial UpdateOn December 19, 2018, Antibe Therapeutics, Inc. (TSX:ATE.V) announced a warrant exercise of nearly all outstanding warrants with an expiration date in December 2018 that r ...
By Brian Marckx, CFANASDAQ:DRRXREAD THE FULL DRRX RESEARCH REPORTPipeline UpdateEarlier this week Durect (NASDAQ:DRRX) provided a corporate and pipeline update. Much of the focus was, as expected, on DUR-928. Particularly noteworthy is that the compa ...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateTreatment with Exebacase Beneficial to S. Aureus Bacteremia Patients On January 7, 2019, ContraFect Corp. (NASDAQ:CFRX) announced topline results from the Phase 2 trial of ...
By David Bautz, PhDNASDAQ:BCLIREAD THE FULL BCLI RESEARCH REPORTBusiness UpdateSet to Initiate Phase 2 Trial in Progressive MSOn December 17, 2018, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration ...
By Lisa ThompsonNASDAQ:CSSEREAD THE FULL CSSE RESEARCH REPORTOn December 28, 2018, Chicken Soup for the Soul Entertainment (NASDAQ:CSSE) purchased the remaining portion of A+ it did not own from the three remaining A+ shareholders. This was comprised ...
By John Vandermosten, CFAOTC:GOVXWe visited with GeoVax (OTC:GOVX) management at their facilities in Smyrna, Georgia to review their key programs and identify the expected path forward for the company. Over the last few years, GeoVax has expanded fro ...
By Brian Marckx, CFANASDAQ:VIVEREAD THE FULL VIVE RESEARCH REPORT12-Month SUI Data, FDA OKs VIVEVE 2 To Progress, LIBERATE U.S. Start-Date Pushed BackIt has been a busy few weeks for Viveve (NASDAQ:VIVE). In addition to raising nearly $19M (net) via ...